• BIO Japan held on Oct.12-14th in Yokohama

    HitGen CEO Dr. Jin Li and Dr. Bill Farley, VP of BD&Licensing, will attend BIO Japan held on Oct.12-14th in Yokohama, which has played a vital role in facilitating interaction between companies and organizations from Japan and abroad for almost 20 years. Looking forward to meeting you there.For more information, click http://www.ics-expo.jp/biojapan/index.html

    BIO Japan held on Oct.12-14th in Yokohama
     
  • New Drug Discovery: Find Needles in Very Large Haystacks

    Aug 23th, as the first speaker of 5th IAPC Meeting, Dr. Jin Li introduced the technical principle of DNA Encoded Library (DELs) synthesis and screening and its potential impact on the early new drug discovery, which attracted several attendees’ interest. Subsequently scientists from all over the world shared their current technology in different research areas. Everyone spoke out freely and gave full play to his strong point during the conference.

    New Drug Discovery: Find Needles in Very Large Haystacks
     
  • Greeting from CEO

    At HitGen, we will do our utmost to understand your business and scientific needs, and to build long-term partnership through high quality and efficient delivery and effective interactions. I look forward to working with you and your organization.

    Greeting from CEO
     
  • Lead Generation by DNA Encoded Chemical Libraries (DELs)

    Using our powerful platform, we provide our partners services which focus on quality, speed and efficiency, delivering value for money. Our products and services include Targets to Hit/Leads, Hits/Leads Expansion, as well as progressing selected programmes to pre-clinical and early clinical stages.

    Lead Generation by DNA Encoded Chemical Libraries (DELs)
     
  • HitGen Enters Into Research Collaboration with Global Blood Therapeutics

    Chengdu, China January 8, 2016 – HitGen LtD, a privately held drug discovery company that enables the extraordinary power of DNA encoded libraries with a patented proprietary platform to discover new therapeutic starting points, announced today a research collaboration with Global Blood Therapeutics, Inc. (NASDAQ: GBT)…

    HitGen Enters Into Research Collaboration with Global Blood Therapeutics
     
  • High-throughput Sequencing

    HitGen has established an Illumina HiSeq 2500 based next-generation DNA sequencing platform. Our DNA sequencing laboratory is built under strict accordance with requirements of ISO17025. HitGen high throughput platform now offers DNA sample preparation and sequencing service including exome capture sequencing, transcriptome sequencing, metagenome sequencing and so on.

    High-throughput Sequencing
     
HitGen: Advancing Innovative Drug Discoveries

Target to Hits/Leads

Custom compound libraries

Collaborative Drug Discovery Programmes with Partners

Research Support


HitGen is a life science company with a focus on hit identification and lead generation. Our core capabilities include medicinal chemistry, computational chemistry, high speed synthesis, cell and molecular biology, in vitro screening and selection. Our core assets are large, diverse and high quality encoded chemical libraries.

We provide products and services to our partners which enable them to progress targets to hits/leads, and eventually to pre-clinical and early clinical stages.


Google+

Link:
hitgenbiomed.com Medicinal Chemistry